CS
ODT

Credit Suisse’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Credit Suisse’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,738
Closed -$47K – 4727
2021
Q1 		$47K Sell
13,738
-5,024
-27% -$95K ﹤0.01% 4230
2020
Q4 		$360K Buy
+18,762
New +$290K ﹤0.01% 3918
2020
Q3 		– Sell
-9,084
Closed -$384K – 4189
2020
Q2 		$384K Buy
+9,084
New +$294K ﹤0.01% 3463
2020
Q1 		– Sell
-10,032
Closed -$326K – 4335
2019
Q4 		$326K Sell
10,032
-2,533
-20% -$78.5K ﹤0.01% 3789
2019
Q3 		$327K Buy
+12,565
New +$420K ﹤0.01% 3657

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Credit Suisse's ODT Position: Q2 2021 in Review

Credit Suisse sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q2 2021, closing a stake of 13,738 shares — an estimated $47K sold.

Credit Suisse first reported a position in ODT in Q3 2019 and held it in 5 quarters. The position peaked at $384K in Q2 2020. 69 funds tracked by Wall St. Rank hold ODT as of Q2 2021.

  • Credit Suisse reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Credit Suisse sold 13,738 Odonate Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $47K.
  • Credit Suisse first reported a position in Odonate Therapeutics, Inc. Common Stock in Q3 2019 and held it in 5 quarters.
  • Credit Suisse's Odonate Therapeutics, Inc. Common Stock position peaked at $384K in Q2 2020.
  • 69 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.